PURPOSE: The aim of this research was to develop a pH-dependent canine absorption model for studying pH effect on both dissolution in vitro and pharmacokinetics in vivo using the weak bases ketoconazole and dipyridamole as model drugs. METHODS: Ketoconazole and dipyridamole pH-dependent dissolution profiles in vitro were determined by dissolution test at different pH values using USP apparatus II and an Opt-Diss Fiber Optic UV System. In vivo absorption studies for ketoconazole and dipyridamole were performed with crossover design in three groups of beagle dogs under control (no treatment), pentagastrin, and famotidine treatments. Ketoconazole and dipyridamole plasma concentrations were quantified by gradient high performance liquid chromatography mass spectroscopy (HPLC MS/MS). Pharmacokinetic parameters were determined from individual plasma concentration vs. time profiles. RESULTS: Ketoconazole and dipyridamole displayed pH-dependent dissolution. Increasing the pH of the dissolution medium from 1.2 to 6.8 reduced the extent of dissolution of ketoconazole and dipyridamole at 1 h by 96% and 92%, respectively. In vivo studies in dogs under control (no treatment), pentagastrin, and famotidine treatments show marked differences in systemic ketoconazole and dipyridamole exposure. Area under the concentration-time curve (AUC) increased more than 4-fold as compared to control group, whereas it increased nearly 30-fold for ketoconazole and 9-fold for dipyridamole with pentagastrin (gastric pH approximately 2-3) as compared to famotidine (gastric pH approximately 5-7.5) treatment. CONCLUSIONS: This work demonstrates a pH-dependent dissolution in vitro and absorption in vivo for the weak bases ketoconazole and dipyridamole independent of food effects. This model is useful to examine pH-dependent effects on oral drug absorption and for screening formulations to overcome the pH dependency.
PURPOSE: The aim of this research was to develop a pH-dependent canine absorption model for studying pH effect on both dissolution in vitro and pharmacokinetics in vivo using the weak bases ketoconazole and dipyridamole as model drugs. METHODS:Ketoconazole and dipyridamole pH-dependent dissolution profiles in vitro were determined by dissolution test at different pH values using USP apparatus II and an Opt-Diss Fiber Optic UV System. In vivo absorption studies for ketoconazole and dipyridamole were performed with crossover design in three groups of beagle dogs under control (no treatment), pentagastrin, and famotidine treatments. Ketoconazole and dipyridamole plasma concentrations were quantified by gradient high performance liquid chromatography mass spectroscopy (HPLC MS/MS). Pharmacokinetic parameters were determined from individual plasma concentration vs. time profiles. RESULTS:Ketoconazole and dipyridamole displayed pH-dependent dissolution. Increasing the pH of the dissolution medium from 1.2 to 6.8 reduced the extent of dissolution of ketoconazole and dipyridamole at 1 h by 96% and 92%, respectively. In vivo studies in dogs under control (no treatment), pentagastrin, and famotidine treatments show marked differences in systemic ketoconazole and dipyridamole exposure. Area under the concentration-time curve (AUC) increased more than 4-fold as compared to control group, whereas it increased nearly 30-fold for ketoconazole and 9-fold for dipyridamole with pentagastrin (gastric pH approximately 2-3) as compared to famotidine (gastric pH approximately 5-7.5) treatment. CONCLUSIONS: This work demonstrates a pH-dependent dissolution in vitro and absorption in vivo for the weak bases ketoconazole and dipyridamole independent of food effects. This model is useful to examine pH-dependent effects on oral drug absorption and for screening formulations to overcome the pH dependency.
Authors: R A Blum; D T D'Andrea; B M Florentino; J H Wilton; D M Hilligoss; M J Gardner; E B Henry; H Goldstein; J J Schentag Journal: Ann Intern Med Date: 1991-05-01 Impact factor: 25.391
Authors: S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; J J Schentag Journal: Antimicrob Agents Chemother Date: 1991-09 Impact factor: 5.191
Authors: V Fainstein; G P Bodey; L Elting; A Maksymiuk; M Keating; K B McCredie Journal: Antimicrob Agents Chemother Date: 1987-01 Impact factor: 5.191
Authors: Sherif I Farag Badawy; David B Gray; Fang Zhao; Duxin Sun; Alan E Schuster; Munir A Hussain Journal: Pharm Res Date: 2006-05-02 Impact factor: 4.200
Authors: Yi-Ling Hsieh; Grace A Ilevbare; Bernard Van Eerdenbrugh; Karl J Box; Manuel Vincente Sanchez-Felix; Lynne S Taylor Journal: Pharm Res Date: 2012-05-12 Impact factor: 4.200
Authors: Andy Z X Zhu; Ming-Chih David Ho; Christopher K Gemski; Bei-Ching Chuang; Mingxiang Liao; Cindy Q Xia Journal: AAPS J Date: 2016-09-06 Impact factor: 4.009
Authors: Christoph Gesenberg; Neil R Mathias; Yan Xu; John Crison; Ishani Savant; Amy Saari; David J Good; Jeffrey N Hemenway; Ajit S Narang; Richard R Schartman; Naiyu Zheng; Adela Buzescu; Jatin Patel Journal: Pharm Res Date: 2019-10-21 Impact factor: 4.200